Abdominal aortic aneurysm

Summary

Abdominal aortic aneurysm (MONDO:0005350) is a disease with 36 cohort genes (256 GWAS associations across 22 studies) and 262 clinical trials. The dominant Reactome pathway is Plasma lipoprotein assembly, remodeling, and clearance (4 cohort genes). Top therapeutic interventions include atorvastatin, canakinumab, and evolocumab.

At a glance

• Cohort genes: 36
• GWAS associations: 256
• Clinical trials: 262

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	abdominal aortic aneurysm
Mondo ID	MONDO:0005350
EFO	EFO:0004214
MeSH	D017544
DOID	DOID:7693
ICD-11	1154633768
SNOMED CT	233985008
UMLS	C0162871
MedGen	56524
Is cancer (heuristic)	no

Also known as: aortic aneurysm, familial abdominal 1

Data availability: 256 GWAS associations (22 studies).

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › aortic disorder › aortic aneurysm › abdominal aortic aneurysm

Related subtypes (1): thoracic aortic aneurysm

Subtypes (1): familial abdominal aortic aneurysm

Genetics & variants

GWAS landscape

256 GWAS associations across 22 studies. Top hits map to 27 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs4977574	2e-114	CDKN2B-AS1	?	0.18
chr9:22093299	8e-57		A	0.18
rs10455872	2e-55	LPA	?	0.24
rs3827066	1e-48	ZNF335	?	0.16
rs12740374	2e-42	CELSR2	?	0.13
rs7994761	1e-39	LINC00540 - FTH1P7	?	0.14
rs429358	5e-39	APOE	?	0.14
rs73015011	3e-38	SMARCA4	?	0.17
rs4936098	7e-36	ADAMTS8, ZBTB44-DT	?	0.11
rs17486278	2e-35	CHRNA5	?	0.1
rs2891168	8e-35	CDKN2B-AS1	G	0.2
rs140570886	1e-34	LPA	?	0.4
rs10757274	2e-33	CDKN2B-AS1	A	1.24
rs434182	1e-32	RBBP8-AS1	?	0.1
rs964184	1e-31	ZPR1	?	0.13
rs7025486	1e-30	DAB2IP	?	0.1
rs731141	3e-30	HDAC1P1, PLCE1	?	0.09
rs12126142	4e-30	IL6R	?	0.09
rs11172113	4e-29	LRP1	?	0.09
rs389877	2e-25	PLTP	G	0.15
rs17688414	2e-24	SUGCT	?	0.09
rs9306894	6e-24	GDF7	?	0.08
rs1660364	4e-22	LINC02775 - SMYD2	?	0.08
chr13:22871446	1e-21		A	0.14
rs1892971	2e-21	RNU7-159P - MMP13	?	0.09
chr18:20172405	3e-21		A	0.11
rs12857403	4e-21	LINC00540 - FTH1P7	A	0.13
rs77925345	3e-20	RNU1-146P - TCP1P3	?	0.14
rs2836411	1e-19	ERG	?	0.08
rs2954021	2e-19	TRIB1AL	?	0.07

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90432152	Roychowdhury T	2023	37,214	997,776	Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target.
GCST90475994	Verma A	2024	16,289	427,111	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90399672	Zhou W	2022	8,163	1,256,755	Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease.
GCST011495	Klarin D	2020	7,642	172,172	Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program.
GCST011496	Klarin D	2020	7,642	172,172	Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program.
GCST003877	Jones GT	2016	4,972	99,858	Meta-Analysis of Genome-Wide Association Studies for Abdominal Aortic Aneurysm Identifies Four New Disease-Specific Risk Loci.
GCST90478019	Verma A	2024	1,773	118,830	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480202	Verma A	2024	1,773	118,830	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST002193	Bradley DT	2013	1,755	5,314	A variant in LDLR is associated with abdominal aortic aneurysm.
GCST001312	Bown MJ	2011	1,737	5,435	Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	3
Tier 2: splice/UTR	4
Tier 3: regulatory	1
Tier 4: intronic/intergenic	42

MAF distribution

Bucket	Variants
common (>=0.05)	50
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	27
intergenic_variant	8
unknown	5
3_prime_UTR_variant	4
missense_variant	3
non_coding_transcript_exon_variant	2
regulatory_region_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs4977574	9	22098575	A>G,T	0.05	intron_variant	CDKN2B-AS1	2e-114	Tier 4: intronic/intergenic
chr9:22093299				0.487			8e-57	Tier 4: intronic/intergenic
rs10455872	6	160589086	A>G	0.05	intron_variant	LPA	2e-55	Tier 4: intronic/intergenic
rs3827066	20	45957384	C>T	0.05	intron_variant	ZNF335	1e-48	Tier 4: intronic/intergenic
rs12740374	1	109274968	G>T	0.05	3_prime_UTR_variant	CELSR2	2e-42	Tier 2: splice/UTR
rs7994761	13	22297307	A>G,T	0.05	intergenic_variant	LINC00540 - FTH1P7	1e-39	Tier 4: intronic/intergenic
rs429358	19	44908684	T>C	0.05	missense_variant	APOE	5e-39	Tier 1: coding
rs73015011	19	11079088	T>C	0.05	intergenic_variant	SMARCA4	3e-38	Tier 4: intronic/intergenic
rs4936098	11	130410772	A>G,T	0.05	intron_variant	ADAMTS8, ZBTB44-DT	7e-36	Tier 4: intronic/intergenic
rs17486278	15	78575140	A>C	0.05	intron_variant	CHRNA5	2e-35	Tier 4: intronic/intergenic
rs2891168	9	22098620	A>G	0.464	intron_variant	CDKN2B-AS1	8e-35	Tier 4: intronic/intergenic
rs140570886	6	160591981	T>C	0.05	intron_variant	LPA	1e-34	Tier 4: intronic/intergenic
rs10757274	9	22096056	A>C,G,T	0.462	intron_variant	CDKN2B-AS1	2e-33	Tier 4: intronic/intergenic
rs434182	18	22702893	C>A,G,T	0.05	intron_variant	RBBP8-AS1	1e-32	Tier 4: intronic/intergenic
rs964184	11	116778201	G>C	0.05	3_prime_UTR_variant	ZPR1	1e-31	Tier 2: splice/UTR
rs7025486	9	121660124	G>A	0.05	intron_variant	DAB2IP	1e-30	Tier 4: intronic/intergenic
rs731141	10	94138924	G>A	0.05	non_coding_transcript_exon_variant	HDAC1P1, PLCE1	3e-30	Tier 4: intronic/intergenic
rs12126142	1	154452980	G>A,C	0.05	intron_variant	IL6R	4e-30	Tier 4: intronic/intergenic
rs11172113	12	57133500	T>C,G	0.05	intron_variant	LRP1	4e-29	Tier 4: intronic/intergenic
rs389877	20	45903845	G>A,C,T	0.204	intron_variant	PLTP	2e-25	Tier 4: intronic/intergenic
rs17688414	7	40801371	C>G,T	0.05	intron_variant	SUGCT	2e-24	Tier 4: intronic/intergenic
rs9306894	2	20678345	A>G	0.05	3_prime_UTR_variant	GDF7	6e-24	Tier 2: splice/UTR
rs1660364	1	214232262	A>C,T	0.05	intron_variant	LINC02775 - SMYD2	4e-22	Tier 4: intronic/intergenic
chr13:22871446				0.219			1e-21	Tier 4: intronic/intergenic
rs1892971	11	102924877	G>A	0.05	regulatory_region_variant	RNU7-159P - MMP13	2e-21	Tier 3: regulatory
chr18:20172405				0.497			3e-21	Tier 4: intronic/intergenic
rs12857403	13	22291470	A>G,T	0.236	intergenic_variant	LINC00540 - FTH1P7	4e-21	Tier 4: intronic/intergenic
rs77925345	12	19777560	A>G	0.05	intron_variant	RNU1-146P - TCP1P3	3e-20	Tier 4: intronic/intergenic
rs2836411	21	38447907	C>A,T	0.05	intron_variant	ERG	1e-19	Tier 4: intronic/intergenic
rs2954021	8	125469835	A>G	0.05	intron_variant	TRIB1AL	2e-19	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 36 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 1

Dual-evidence genes (GWAS + Mendelian — highest-confidence targets)

Gene	HGNC	Evidence routes
FBN1	FBN1	GWAS, Orphanet

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ZNF335	Orphanet:329228	Microcephalic primordial dwarfism due to ZNF335 deficiency
FERMT1	Orphanet:2908	Kindler epidermolysis bullosa
APOA5	Orphanet:530849	Familial apolipoprotein A5 deficiency
CDKN2A	Orphanet:1333	Familial pancreatic carcinoma
CDKN2A	Orphanet:1501	Adrenocortical carcinoma
CDKN2A	Orphanet:252206	Melanoma and neural system tumor syndrome
CDKN2A	Orphanet:404560	Familial atypical multiple mole melanoma syndrome
CDKN2A	Orphanet:524	Li-Fraumeni syndrome
CDKN2A	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
CDKN2A	Orphanet:618	Familial melanoma
CDKN2A	Orphanet:99861	Precursor T-cell acute lymphoblastic leukemia
CDKN2B	Orphanet:618	Familial melanoma
CDKN2B	Orphanet:652	Multiple endocrine neoplasia type 1
PCSK9	Orphanet:391665	Homozygous familial hypercholesterolemia
ERG	Orphanet:319	Skeletal Ewing sarcoma
ERG	Orphanet:370334	Extraskeletal Ewing sarcoma
FBN1	Orphanet:1885	Isolated ectopia lentis
FBN1	Orphanet:2084	Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome
FBN1	Orphanet:2462	Shprintzen-Goldberg syndrome
FBN1	Orphanet:2623	Geleophysic dysplasia
FBN1	Orphanet:2833	Stiff skin syndrome
FBN1	Orphanet:284963	Marfan syndrome type 1
FBN1	Orphanet:284979	Neonatal Marfan syndrome
FBN1	Orphanet:300382	Progeroid and marfanoid aspect-lipodystrophy syndrome
FBN1	Orphanet:3449	Weill-Marchesani syndrome
FBN1	Orphanet:91387	Familial thoracic aortic aneurysm and aortic dissection
FBN1	Orphanet:969	Acromicric dysplasia
IL6R	Orphanet:656326	Autosomal recessive combined immunodeficiency due to IL6R deficiency
APOE	Orphanet:329481	Lipoprotein glomerulopathy
APOE	Orphanet:412	Dysbetalipoproteinemia
LDLR	Orphanet:391665	Homozygous familial hypercholesterolemia
LRP1	Orphanet:2340	Keratosis follicularis spinulosa decalvans
LRP1	Orphanet:79100	Atrophoderma vermiculata
MMP9	Orphanet:1040	Metaphyseal anadysplasia
RBBP8	Orphanet:313795	Jawad syndrome
RBBP8	Orphanet:808	Seckel syndrome

Cohort genes → proteins

36 cohort genes, 34 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	36

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SORT1	HGNC:11186	ENSG00000134243	Q99523	Sortilin	gwas
ZPR1	HGNC:13051	ENSG00000109917	O75312	Zinc finger protein ZPR1	gwas
MEPE	HGNC:13361	ENSG00000152595	Q9NQ76	Matrix extracellular phosphoglycoprotein	gwas
ZNF335	HGNC:15807	ENSG00000198026	Q9H4Z2	Zinc finger protein 335	gwas
FERMT1	HGNC:15889	ENSG00000101311	Q9BQL6	Fermitin family homolog 1	gwas
ABHD16B	HGNC:16128	ENSG00000183260	Q9H3Z7	ABHD16B	gwas
PCIF1	HGNC:16200	ENSG00000100982	Q9H4Z3	mRNA (2’-O-methyladenosine-N(6)-)-methyltransferase	gwas
TRIB1	HGNC:16891	ENSG00000173334	Q96RU8	Tribbles homolog 1	gwas
APOA5	HGNC:17288	ENSG00000110243	Q6Q788	Apolipoprotein A-V	gwas
DAB2IP	HGNC:17294	ENSG00000136848	Q5VWQ8	Disabled homolog 2-interacting protein	gwas
CDKN2A	HGNC:1787	ENSG00000147889	P42771	Cyclin-dependent kinase inhibitor 2A	gwas
CDKN2B	HGNC:1788	ENSG00000147883	P42772	Cyclin-dependent kinase 4 inhibitor B	gwas
SCGB1D1	HGNC:18395	ENSG00000168515	O95968	Secretoglobin family 1D member 1	gwas
CHRNA3	HGNC:1957	ENSG00000080644	P32297	Neuronal acetylcholine receptor subunit alpha-3	gwas
PCSK9	HGNC:20001	ENSG00000169174	Q8NBP7	Proprotein convertase subtilisin/kexin type 9	gwas
SMYD2	HGNC:20982	ENSG00000143499	Q9NRG4	N-lysine methyltransferase SMYD2	gwas
ADAMTS8	HGNC:224	ENSG00000134917	Q9UP79	A disintegrin and metalloproteinase with thrombospondin motifs 8	gwas
CTAGE1	HGNC:24346	ENSG00000212710	Q96RT6	cTAGE family member 2	gwas
PSRC1	HGNC:24472	ENSG00000134222	Q6PGN9	Proline/serine-rich coiled-coil protein 1	gwas
CRISPLD2	HGNC:25248	ENSG00000103196	Q9H0B8	Cysteine-rich secretory protein LCCL domain-containing 2	gwas
ANKRD44	HGNC:25259	ENSG00000065413	Q8N8A2	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B	gwas
LDAH	HGNC:26145	ENSG00000118961	Q9H6V9	Lipid droplet-associated hydrolase	gwas
CELSR2	HGNC:3231	ENSG00000143126	Q9HCU4	Cadherin EGF LAG seven-pass G-type receptor 2	gwas
CDPF1	HGNC:33710	ENSG00000205643	Q6NVV7	Cysteine-rich DPF motif domain-containing protein 1	gwas
CDKN2B-AS1	HGNC:34341	ENSG00000240498		CDKN2B and CDKN2A antisense cis and trans regulatory RNA 1	gwas
ERG	HGNC:3446	ENSG00000157554	P11308	Transcriptional regulator ERG	gwas
FBN1	HGNC:3603	ENSG00000166147	P35555	Fibrillin-1	gwas
GDF7	HGNC:4222	ENSG00000143869	Q7Z4P5	Growth/differentiation factor 7	gwas
LINC00540	HGNC:43673	ENSG00000276476		long intergenic non-protein coding RNA 540	gwas
IL6R	HGNC:6019	ENSG00000160712	P08887	Interleukin-6 receptor subunit alpha	gwas
APOE	HGNC:613	ENSG00000130203	P02649	Apolipoprotein E	gwas
LDLR	HGNC:6547	ENSG00000130164	P01130	Low-density lipoprotein receptor	gwas
LPA	HGNC:6667	ENSG00000198670	P08519	Apolipoprotein(a)	gwas
LRP1	HGNC:6692	ENSG00000123384	Q07954	Prolow-density lipoprotein receptor-related protein 1	gwas
MMP9	HGNC:7176	ENSG00000100985	P14780	Matrix metalloproteinase-9	gwas
RBBP8	HGNC:9891	ENSG00000101773	Q99708	DNA endonuclease RBBP8	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SORT1	Sortilin	Functions as a sorting receptor in the Golgi compartment and as a clearance receptor on the cell surface.
ZPR1	Zinc finger protein ZPR1	Acts as a signaling molecule that communicates proliferative growth signals from the cytoplasm to the nucleus.
MEPE	Matrix extracellular phosphoglycoprotein	Promotes renal phosphate excretion and inhibits intestinal phosphate absorption.
ZNF335	Zinc finger protein 335	Component or associated component of some histone methyltransferase complexes may regulate transcription through recruitment of those complexes on gene promoters.
FERMT1	Fermitin family homolog 1	Involved in cell adhesion.
ABHD16B	ABHD16B	Hydrolyzes the sn-1 position of glycerophospholipids with high specificity towards phosphatidylserine (PS), PS-PLA1 enzyme.
PCIF1	mRNA (2’-O-methyladenosine-N(6)-)-methyltransferase	Cap-specific adenosine methyltransferase that catalyzes formation of N(6),2’-O-dimethyladenosine cap (m6A(m)) by methylating the adenosine at the second transcribed position of capped mRNAs.
TRIB1	Tribbles homolog 1	Adapter protein involved in protein degradation by interacting with COP1 ubiquitin ligase.
APOA5	Apolipoprotein A-V	Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL.
DAB2IP	Disabled homolog 2-interacting protein	Functions as a scaffold protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways.
CDKN2A	Cyclin-dependent kinase inhibitor 2A	Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6.
CDKN2B	Cyclin-dependent kinase 4 inhibitor B	Interacts strongly with CDK4 and CDK6.
SCGB1D1	Secretoglobin family 1D member 1	May bind androgens and other steroids, may also bind estramustine, a chemotherapeutic agent used for prostate cancer.
CHRNA3	Neuronal acetylcholine receptor subunit alpha-3	Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection…
PCSK9	Proprotein convertase subtilisin/kexin type 9	Crucial player in the regulation of plasma cholesterol homeostasis.
SMYD2	N-lysine methyltransferase SMYD2	Protein-lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53/TP53 and RB1.
ADAMTS8	A disintegrin and metalloproteinase with thrombospondin motifs 8	Has anti-angiogenic properties.
PSRC1	Proline/serine-rich coiled-coil protein 1	Required for normal progression through mitosis.
CRISPLD2	Cysteine-rich secretory protein LCCL domain-containing 2	Promotes matrix assembly.
ANKRD44	Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B	Putative regulatory subunit of protein phosphatase 6 (PP6) that may be involved in the recognition of phosphoprotein substrates.
LDAH	Lipid droplet-associated hydrolase	Probable serine lipid hydrolase associated with lipid droplets.
CELSR2	Cadherin EGF LAG seven-pass G-type receptor 2	Receptor that may have an important role in cell/cell signaling during nervous system formation.
ERG	Transcriptional regulator ERG	Transcriptional regulator.
FBN1	Fibrillin-1	Structural component of the 10-12 nm diameter microfibrils of the extracellular matrix, which conveys both structural and regulatory properties to load-bearing connective tissues.
GDF7	Growth/differentiation factor 7	May play an active role in the motor area of the primate neocortex.
IL6R	Interleukin-6 receptor subunit alpha	Part of the receptor for interleukin 6.
APOE	Apolipoprotein E	APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids.
LDLR	Low-density lipoprotein receptor	Binds low density lipoprotein /LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis.
LPA	Apolipoprotein(a)	Apo(a) is the main constituent of lipoprotein(a) (Lp(a)).
LRP1	Prolow-density lipoprotein receptor-related protein 1	Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells.
MMP9	Matrix metalloproteinase-9	Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration.
RBBP8	DNA endonuclease RBBP8	Endonuclease that cooperates with the MRE11-RAD50-NBN (MRN) complex in DNA-end resection, the first step of double-strand break (DSB) repair through the homologous recombination (HR) pathway.

Protein-family classification

Druggable: 7 · Difficult: 10 · Unknown: 19 · Druggable fraction: 0.19

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	7	3.4×	0.028
Protease	4	4.1×	0.057
Other/Unknown	19	0.9×	0.828
Antibody/Immunoglobulin	1	0.8×	0.828
Kinase	1	0.8×	0.828
Transcription factor	3	0.7×	0.828
GPCR	1	0.7×	0.828

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SORT1	Scaffold/PPI	no		VPS10, WD40/YVTN_repeat-like_dom_sf, Sortilin_C
ZPR1	Transcription factor	no		Znf_ZPR1, ZPR1, ZPR1_A/B_dom
MEPE	Other/Unknown	no		MEPE
ZNF335	Transcription factor	no		Znf_C2H2_type, Znf_C2H2_sf, Zinc_finger/UBP_domain
FERMT1	Scaffold/PPI	no		PH_domain, PH-like_dom_sf, FERM_central
ABHD16B	Other/Unknown	no		AB_hydrolase_1, AB_hydrolase_fold
PCIF1	Scaffold/PPI	no		WW_dom, PCIF1_WW, HSP70_C_sf
TRIB1	Kinase	yes		Prot_kinase_dom, Kinase-like_dom_sf, Tribbles/Ser_Thr_kinase_40
APOA5	Other/Unknown	no		ApoA_E, Apolipoprotein_A1/A4/E
DAB2IP	Scaffold/PPI	no		C2_dom, PH_domain, RasGAP_dom
CDKN2A	Scaffold/PPI	no		Ankyrin_rpt-contain_sf, Ank_Repeat/CDKN_Inhibitor, Tumor_suppres_ARF
CDKN2B	Scaffold/PPI	no		Ankyrin_rpt, Ankyrin_rpt-contain_sf, Ank_Repeat/CDKN_Inhibitor
SCGB1D1	Other/Unknown	no		Secretoglobin, Secretoglobin_sf
CHRNA3	Other/Unknown	no		Nicotinic_acetylcholine_rcpt, Neurotrans-gated_channel_TM, Neur_channel
PCSK9	Protease	yes	3.4.21.61	Peptidase_S8/S53_dom, S8pro/Inhibitor_I9, Peptidase_S8_subtilisin-rel
SMYD2	Transcription factor	no		SET_dom, Znf_MYND, TPR-like_helical_dom_sf
ADAMTS8	Protease	yes		TSP1_rpt, Peptidase_M12B, Peptidase_M12B_N
CTAGE1	Other/Unknown	no		cTAGE_MIA/OTOR
PSRC1	Other/Unknown	no		DDA3/GTSE-1, GTSE1_N
CRISPLD2	Other/Unknown	no		CRISP-related, LCCL, CAP_dom
ANKRD44	Scaffold/PPI	no		Ankyrin_rpt, Ankyrin_rpt-contain_sf
LDAH	Other/Unknown	no		LDAH, AB_hydrolase_fold
CELSR2	GPCR	yes		EGF-type_Asp/Asn_hydroxyl_site, GPS, EGF
CDPF1	Other/Unknown	no		CDPF1_dom, CDPF1
CDKN2B-AS1	Other/Unknown	no
ERG	Other/Unknown	no		Ets_dom, Pointed_dom, SAM/pointed_sf
FBN1	Other/Unknown	no		EGF-type_Asp/Asn_hydroxyl_site, EGF, EGF-like_Ca-bd_dom
GDF7	Other/Unknown	no		TGF-b_propeptide, TGF-b_C, TGF-beta-like
LINC00540	Other/Unknown	no
IL6R	Antibody/Immunoglobulin	yes		Hematopoietin_rcpt_L_F3_CS, Ig_sub2, Ig_sub
APOE	Other/Unknown	no		ApoA_E, Apolipoprotein_A1/A4/E
LDLR	Other/Unknown	no		LDLR_classB_rpt, EGF-type_Asp/Asn_hydroxyl_site, EGF
LPA	Protease	yes		Kringle, Trypsin_dom, Peptidase_S1A
LRP1	Other/Unknown	no		LDLR_classB_rpt, EGF-type_Asp/Asn_hydroxyl_site, EGF
MMP9	Protease	yes	3.4.24.35	FN_type2_dom, Hemopexin-like_dom, Pept_M10_metallopeptidase
RBBP8	Other/Unknown	no		Ctp1_C, CtIP_N, RBBP8-like

Expression context

Cohort genes with no expression data: 0.

30 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	1
broad (>20)	35
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	4
right testis	3
tibia	3
right lobe of liver	3
primordial germ cell in gonad	3
adrenal tissue	3
ganglionic eminence	2
periodontal ligament	2
trabecular bone tissue	2
cerebellar hemisphere	2
right hemisphere of cerebellum	2
colonic mucosa	2
mucosa of sigmoid colon	2
left testis	2
testis	2
liver	2
blood vessel layer	2
choroid plexus epithelium	2
mucosa of transverse colon	2
apex of heart	2

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SORT1	291	ubiquitous	marker	inferior vagus X ganglion, corpus epididymis, subthalamic nucleus
ZPR1	267	ubiquitous	marker	cortical plate, ganglionic eminence, right testis
MEPE	52	tissue_specific	marker	tibia, periodontal ligament, trabecular bone tissue
ZNF335	199	ubiquitous	marker	granulocyte, right hemisphere of cerebellum, cerebellar hemisphere
FERMT1	235	ubiquitous	marker	mucosa of sigmoid colon, colonic mucosa, gingival epithelium
ABHD16B	106		yes	right testis, left testis, testis
PCIF1	231	ubiquitous	marker	mucosa of stomach, body of uterus, left uterine tube
TRIB1	280	ubiquitous	marker	mucosa of urinary bladder, mucosa of sigmoid colon, visceral pleura
APOA5	45	tissue_specific	yes	right lobe of liver, liver, skeletal muscle tissue of rectus abdominis
DAB2IP	254	ubiquitous	marker	right hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex
CDKN2A	220	ubiquitous	marker	parotid gland, cervix squamous epithelium, pituitary gland
CDKN2B	219	ubiquitous	marker	jejunal mucosa, colonic mucosa, lower esophagus mucosa
SCGB1D1	34	tissue_specific	marker	right uterine tube, blood vessel layer, choroid plexus epithelium
CHRNA3	179	broad	marker	pigmented layer of retina, thymus, primordial germ cell in gonad
PCSK9	147	broad	marker	right lobe of liver, mucosa of transverse colon, male germ line stem cell (sensu Vertebrata) in testis
SMYD2	285	ubiquitous	marker	left ventricle myocardium, heart right ventricle, apex of heart
ADAMTS8	197	tissue_specific	marker	middle temporal gyrus, upper lobe of left lung, upper lobe of lung
CTAGE1	13	tissue_specific	yes	right testis, left testis, testis
PSRC1	222	ubiquitous	yes	C1 segment of cervical spinal cord, ventricular zone, spinal cord
CRISPLD2	278	ubiquitous	marker	decidua, tibia, pericardium
ANKRD44	248	ubiquitous	marker	monocyte, leukocyte, bone marrow cell
LDAH	254	ubiquitous	marker	adrenal tissue, male germ line stem cell (sensu Vertebrata) in testis, islet of Langerhans
CELSR2	248	ubiquitous	marker	ganglionic eminence, ventricular zone, right frontal lobe
CDPF1	174	ubiquitous	yes	pancreatic ductal cell, tibialis anterior, apex of heart
CDKN2B-AS1	169	ubiquitous	marker	mucosa of transverse colon, rectum, transverse colon
ERG	247	broad	marker	tendon of biceps brachii, descending thoracic aorta, thoracic aorta
FBN1	275	ubiquitous	marker	synovial joint, skin of hip, decidua
GDF7	168	broad	marker	seminal vesicle, endometrium, blood vessel layer
LINC00540	136	broad	yes	male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, buccal mucosa cell
IL6R	271	ubiquitous	marker	blood, monocyte, leukocyte

Protein interactions among cohort

Intra-cohort edges: 19.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CDKN2A	9,311
APOE	6,793
MMP9	6,708
FBN1	3,640
CDKN2B	3,431
RBBP8	3,235
PCSK9	2,994
IL6R	2,805
LRP1	2,662
ZPR1	2,581

Intra-cohort edges

A	B	Sources
APOA5	APOE	string_interaction
APOA5	PSRC1	string_interaction
APOA5	TRIB1	string_interaction
APOA5	ZPR1	string_interaction
APOE	LDLR	intact
APOE	LPA	string_interaction
APOE	LRP1	intact, string_interaction
CDKN2A	CDKN2B	biogrid_interaction
CELSR2	PCSK9	string_interaction
CELSR2	PSRC1	string_interaction
CELSR2	SORT1	string_interaction
LDLR	PCSK9	biogrid_interaction, intact, string_interaction
LPA	PCSK9	string_interaction
LRP1	MMP9	string_interaction
PCIF1	ZNF335	string_interaction
PCSK9	PSRC1	string_interaction
PCSK9	SORT1	string_interaction
PSRC1	SORT1	string_interaction
SORT1	TRIB1	string_interaction

Structural data

PDB: 16 · AlphaFold-only: 18 · No structure: 2

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
PCSK9	Q8NBP7	65
LDLR	P01130	36
APOE	P02649	29
MMP9	P14780	29
SMYD2	Q9NRG4	25
SORT1	Q99523	17
LPA	P08519	16
FBN1	P35555	11
IL6R	P08887	10
ERG	P11308	8
LRP1	Q07954	7
TRIB1	Q96RU8	5
CDKN2A	P42771	5
CHRNA3	P32297	5
RBBP8	Q99708	4
PCIF1	Q9H4Z3	3

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
LDAH	Q9H6V9	90.59
ANKRD44	Q8N8A2	90.57
CDKN2B	P42772	90.12
SCGB1D1	O95968	89.74
CDPF1	Q6NVV7	87.30
ABHD16B	Q9H3Z7	86.64
FERMT1	Q9BQL6	81.14
CRISPLD2	Q9H0B8	80.67
ADAMTS8	Q9UP79	80.22
ZPR1	O75312	80.11
APOA5	Q6Q788	72.38
GDF7	Q7Z4P5	72.03
CTAGE1	Q96RT6	70.45
DAB2IP	Q5VWQ8	65.74
PSRC1	Q6PGN9	57.83
ZNF335	Q9H4Z2	52.13
MEPE	Q9NQ76	43.45
CELSR2	Q9HCU4

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 173. Enrichment computed across 36 evidence-associated genes (21 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 21 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Plasma lipoprotein assembly, remodeling, and clearance	4	43.5×	2e-04	APOA5, APOE, LDLR, LPA
Post-translational protein phosphorylation	5	23.9×	2e-04	MEPE, APOA5, PCSK9, FBN1, APOE
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	5	20.6×	2e-04	MEPE, APOA5, PCSK9, FBN1, APOE
Plasma lipoprotein remodeling	3	68.0×	5e-04	APOA5, APOE, LPA
Metabolism of fat-soluble vitamins	3	54.4×	7e-04	APOE, LDLR, LRP1
Chylomicron clearance	2	217.5×	9e-04	APOE, LDLR
Visual phototransduction	3	37.1×	0.002	APOE, LDLR, LRP1
Retinoid metabolism and transport	3	35.5×	0.002	APOE, LDLR, LRP1
Chylomicron remodeling	2	108.8×	0.003	APOA5, APOE
Binding and Uptake of Ligands by Scavenger Receptors	2	51.8×	0.010	APOE, LRP1
LDL clearance	2	51.8×	0.010	PCSK9, LDLR
Degradation of the extracellular matrix	3	16.8×	0.010	ADAMTS8, FBN1, MMP9
Metabolism of vitamins and cofactors	3	16.6×	0.010	APOE, LDLR, LRP1
Plasma lipoprotein clearance	2	45.3×	0.011	APOE, LDLR
G1 Phase	2	37.5×	0.014	CDKN2A, CDKN2B
Sensory Perception	3	13.6×	0.014	APOE, LDLR, LRP1
Evasion of Oncogene Induced Senescence Due to p14ARF Defects	1	543.8×	0.017	CDKN2A
Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects	1	543.8×	0.017	CDKN2A
Oncogene Induced Senescence	2	32.0×	0.017	CDKN2A, CDKN2B
Vesicle-mediated transport	4	6.6×	0.023	SORT1, APOE, LDLR, LRP1
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4	1	271.9×	0.026	CDKN2A
Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4	1	271.9×	0.026	CDKN2A
Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function	1	271.9×	0.026	CDKN2A
Cyclin D associated events in G1	2	22.2×	0.026	CDKN2A, CDKN2B
Post-translational protein modification	5	4.6×	0.026	MEPE, APOA5, CDKN2A, ADAMTS8, APOE
Diseases of Cellular Senescence	1	181.3×	0.031	CDKN2A
Evasion of Oncogene Induced Senescence Due to p16INK4A Defects	1	181.3×	0.031	CDKN2A
Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6	1	181.3×	0.031	CDKN2A
Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects	1	181.3×	0.031	CDKN2A
Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6	1	181.3×	0.031	CDKN2A

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 31 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cholesterol homeostasis	5	25.2×	7e-04	APOA5, PCSK9, LDAH, APOE, LDLR
positive regulation of low-density lipoprotein particle receptor catabolic process	2	362.4×	0.002	PCSK9, APOE
negative regulation of receptor recycling	2	217.4×	0.002	PCSK9, LDLR
very-low-density lipoprotein particle clearance	2	217.4×	0.002	APOA5, APOE
acylglycerol homeostasis	2	217.4×	0.002	APOA5, APOE
positive regulation of lysosomal protein catabolic process	2	217.4×	0.002	LDLR, LRP1
cholesterol metabolic process	4	25.3×	0.002	APOA5, PCSK9, APOE, LDLR
triglyceride metabolic process	3	42.9×	0.003	APOA5, PCSK9, APOE
high-density lipoprotein particle clearance	2	155.3×	0.003	APOE, LDLR
lipoprotein catabolic process	2	155.3×	0.003	APOE, LDLR
regulation of protein metabolic process	2	135.9×	0.003	APOE, LDLR
negative regulation of protein metabolic process	2	135.9×	0.003	APOE, LDLR
amyloid-beta clearance by cellular catabolic process	2	135.9×	0.003	LDLR, LRP1
positive regulation of amyloid-beta clearance	2	135.9×	0.003	APOE, LRP1
negative regulation of MAPK cascade	3	29.1×	0.005	TRIB1, DAB2IP, APOE
negative regulation of low-density lipoprotein particle clearance	2	98.8×	0.005	PCSK9, LDLR
negative regulation of smooth muscle cell migration	2	98.8×	0.005	TRIB1, LRP1
response to caloric restriction	2	98.8×	0.005	APOE, LDLR
negative regulation of amyloid fibril formation	2	83.6×	0.007	APOE, LDLR
phospholipid efflux	2	72.5×	0.008	APOA5, APOE
regulation of cholesterol metabolic process	2	72.5×	0.008	APOE, LDLR
receptor-mediated endocytosis	3	21.5×	0.008	APOE, LDLR, LRP1
lipoprotein metabolic process	2	60.4×	0.010	APOA5, PCSK9
amyloid-beta clearance	2	60.4×	0.010	LDLR, LRP1
synaptic transmission, cholinergic	2	51.8×	0.013	CHRNA3, APOE
positive regulation of endocytosis	2	51.8×	0.013	APOE, LRP1
negative regulation of endothelial cell migration	2	49.4×	0.013	DAB2IP, APOE
negative regulation of cell population proliferation	5	6.8×	0.013	DAB2IP, CDKN2A, CDKN2B, SMYD2, ADAMTS8
regulation of protein-containing complex assembly	2	47.3×	0.014	DAB2IP, APOE
lysosomal transport	2	45.3×	0.015	PCSK9, LRP1

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Tranexamic Acid	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amlodipine, Canakinumab, Cyclosporine, Metformin, Pemirolast, Perindopril, Ticagrelor.

Drug target analysis

Approved (phase 4): 4 · Phase ≥3: 5 · Phased (≥1): 5 · Undrugged: 31

Druggability breadth: 15 of 36 evidence-associated genes (42%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CHRNA3	VARENICLINE
PCSK9	NILOTINIB
LDLR	NILOTINIB
MMP9	CHLOROXINE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MMP9	26	4
CHRNA3	21	4
SORT1	1	3
PCSK9	1	4
LDLR	1	4
ZPR1	0	0
MEPE	0	0
ZNF335	0	0
FERMT1	0	0
ABHD16B	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
VARENICLINE	4	CHRNA3
MECAMYLAMINE	4	CHRNA3
NICOTINE	4	CHRNA3
ONDANSETRON	4	CHRNA3
TROPISETRON	4	CHRNA3
ACETYLCHOLINE	4	CHRNA3
BUPROPION	4	CHRNA3
GRANISETRON	4	CHRNA3
NILOTINIB	4	LDLR, PCSK9
CHLOROXINE	4	MMP9
BUDESONIDE	4	MMP9
PRAZOSIN	4	MMP9
ZOLEDRONIC ACID	4	MMP9
SECOBARBITAL	4	MMP9
DACARBAZINE	4	MMP9
CHLORHEXIDINE	4	MMP9
ECONAZOLE	4	MMP9
BUSULFAN	4	MMP9
REMINERTANT	3	SORT1
DEXMECAMYLAMINE	3	CHRNA3
CYTISINICLINE	3	CHRNA3
CURCUMIN	3	MMP9
CAFFEIC ACID	3	MMP9
MARIMASTAT	3	MMP9
QUERCETIN	3	MMP9
PRINOMASTAT	3	MMP9
ALTINICLINE	2	CHRNA3
RADAFAXINE	2	CHRNA3
ANABASEINE	2	CHRNA3
STILONIUM IODIDE	2	CHRNA3

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MMP9	713	Binding:685, ADMET:20, Functional:8
CHRNA3	436	Binding:343, Functional:91, ADMET:2
PCSK9	202	Binding:201, ADMET:1
SMYD2	148	Binding:148
LDLR	55	Binding:54, Functional:1
SORT1	17	Binding:15, ADMET:2
ERG	14	Binding:10, Functional:3, ADMET:1
DAB2IP	8	Binding:8
IL6R	5	Binding:5
FERMT1	2	Binding:2
CDKN2A	2	Binding:2
PCIF1	1	Binding:1
TRIB1	1	Binding:1
ANKRD44	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PCSK9	3.4.21.61	Kexin
MMP9	3.4.24.35	gelatinase B

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CHRNA3	436
PCSK9	202
SMYD2	148
MMP9	713

Pharmacogenomics

Cohort genes with a PharmGKB record: 35; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

29 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
VARENICLINE	4	CHRNA3
MECAMYLAMINE	4	CHRNA3
NICOTINE	4	CHRNA3
ONDANSETRON	4	CHRNA3
TROPISETRON	4	CHRNA3
ACETYLCHOLINE	4	CHRNA3
BUPROPION	4	CHRNA3
GRANISETRON	4	CHRNA3
NILOTINIB	4	LDLR, PCSK9
CHLOROXINE	4	MMP9
BUDESONIDE	4	MMP9
PRAZOSIN	4	MMP9
ZOLEDRONIC ACID	4	MMP9
SECOBARBITAL	4	MMP9
DACARBAZINE	4	MMP9
CHLORHEXIDINE	4	MMP9
ECONAZOLE	4	MMP9
BUSULFAN	4	MMP9
REMINERTANT	3	SORT1
DEXMECAMYLAMINE	3	CHRNA3
CYTISINICLINE	3	CHRNA3
CAFFEIC ACID	3	MMP9
MARIMASTAT	3	MMP9
QUERCETIN	3	MMP9
PRINOMASTAT	3	MMP9
ALTINICLINE	2	CHRNA3
RADAFAXINE	2	CHRNA3
ANABASEINE	2	CHRNA3
STILONIUM IODIDE	2	CHRNA3

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	4	CHRNA3, PCSK9, LDLR, MMP9
B	Phased (≥1) drug, not yet approved	1	SORT1
C	Druggable family + PDB, no drug	3	TRIB1, IL6R, LPA
D	Druggable family + AlphaFold only, no drug	2	ADAMTS8, CELSR2
E	Difficult family or no structure, no drug	26	ZPR1, MEPE, ZNF335, FERMT1, ABHD16B, PCIF1, APOA5, DAB2IP, CDKN2A, CDKN2B (+16 more)

Undrugged target profiles

31 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
PSRC1	0	SORT1, PCSK9
CELSR2	0	SORT1, PCSK9
SMYD2	148	—
ZPR1	0	—
MEPE	0	—
ZNF335	0	—
FERMT1	2	—
ABHD16B	0	—
PCIF1	1	—
TRIB1	1	—
APOA5	0	—
DAB2IP	8	—
CDKN2A	2	—
CDKN2B	0	—
SCGB1D1	0	—
ADAMTS8	0	—
CTAGE1	0	—
CRISPLD2	0	—
ANKRD44	1	—
LDAH	0	—
CDPF1	0	—
CDKN2B-AS1	0	—
ERG	14	—
FBN1	0	—
GDF7	0	—
LINC00540	0	—
IL6R	5	—
APOE	0	—
LPA	0	—
LRP1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 262.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	228
PHASE2	9
PHASE1	7
PHASE4	5
EARLY_PHASE1	5
PHASE2/PHASE3	4
PHASE3	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00662480	PHASE4	UNKNOWN	Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark
NCT01062802	PHASE4	COMPLETED	Statin Use in Abdominal Aortic Aneurysm Repair
NCT01683084	PHASE4	COMPLETED	Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms
NCT03231397	PHASE4	TERMINATED	Predictors of AAA Expansion and/or Rupture
NCT04061798	PHASE4	TERMINATED	ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair.
NCT06001918	PHASE2/PHASE3	RECRUITING	Nectero EAST System Clinical Study
NCT00233688	PHASE3	COMPLETED	Study of the Endovascular QUANTUM LP™ Stent Graft System in Abdominal Aortic Aneurysms (AAA)
NCT00442065	PHASE2/PHASE3	COMPLETED	ARBITER-II: Aorfix™ Bifurcated Safety and Performance Trial: Phase II, Angulated Vessels
NCT01225094	PHASE2/PHASE3	COMPLETED	Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair
NCT01368679	PHASE3	WITHDRAWN	A Clinical Study to Evaluate the Safety and Performance of the Modular AAA Stent-Graft System
NCT02125890	PHASE3	COMPLETED	Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms
NCT03507413	PHASE2/PHASE3	UNKNOWN	Metformin Therapy in Non-diabetic AAA Patients
NCT04500756	PHASE2	RECRUITING	Limiting AAA With Metformin (LIMIT) Trial
NCT00235118	PHASE1/PHASE2	COMPLETED	Cordis Bilateral AAA Device Compared to Open Surgical Repair of Abdominal Aortic Aneurysms (ARIBA)
NCT00246038	PHASE2	WITHDRAWN	The Boston Scientific ENOVUS Trial
NCT00610090	PHASE2	TERMINATED	Safety Study for the Treatment of Abdominal Aortic Aneurysms
NCT01118520	PHASE2	COMPLETED	AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
NCT01354184	PHASE2	COMPLETED	CRD007 for the Treatment of Abdominal Aorta Aneurysm (The AORTA Trial)
NCT02007252	PHASE2	TERMINATED	ACZ885 for the Treatment of Abdominal Aortic Aneurysm
NCT02022436	PHASE2	COMPLETED	Evaluation of Predictors of Aortic Aneurysm Growth and Rupture
NCT02070653	PHASE2	COMPLETED	The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion
NCT04224051	PHASE2	UNKNOWN	Metformin for Abdominal Aortic Aneurysm Growth Inhibition
NCT00646048	PHASE1	COMPLETED	A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms
NCT01082185	PHASE1	COMPLETED	South American Abdominal Stent Graft Trial
NCT01328197	PHASE1	COMPLETED	Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms
NCT01346943	PHASE1	UNKNOWN	The Altura Abdominal Aortic Aneurysm (AAA) Endograft Safety and Feasibility Study
NCT02295137	PHASE1	UNKNOWN	Image Fusion of Preprocedural CTA With Real Time Fluoroscopy to Enhance EVAR Repair
NCT02469376	PHASE1	TERMINATED	Evaluation of a New Imagingtechnologie for Thrombosis
NCT02846883	PHASE1	TERMINATED	Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms
NCT06081153	EARLY_PHASE1	NOT_YET_RECRUITING	Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
NCT07473102	EARLY_PHASE1	RECRUITING	PET Imaging of MMP Activation in AAA: Clinical Component
NCT01882634	EARLY_PHASE1	COMPLETED	Screening Programme for Abdominal Aortic Aneurysm by Hand-Held-Ultrasonography in Primary Health Care
NCT04586452	EARLY_PHASE1	COMPLETED	NIH CCR2 AAA Study
NCT04592991	EARLY_PHASE1	TERMINATED	CCR2 AAA Pilot Study
NCT01248533	Not specified	ENROLLING_BY_INVITATION	Screening for Abdominal Aortic Aneurysm in 65 Year Old Males in Oslo
NCT01538056	Not specified	RECRUITING	Physician Modified Endovascular Grafts
NCT02009644	Not specified	ACTIVE_NOT_RECRUITING	Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms
NCT02387255	Not specified	RECRUITING	Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
NCT02548546	Not specified	RECRUITING	Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques
NCT03180996	Not specified	ACTIVE_NOT_RECRUITING	Global Fenestrated Anaconda Clinical STudy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ATORVASTATIN	4	1
CANAKINUMAB	4	1
EVOLOCUMAB	4	1
FLUORODOPA F 18	4	1
IODIXANOL	4	1
PERINDOPRIL ARGININE	4	1
TELMISARTAN	4	1
CURCUMIN	3	1
CHEMBL4587343	0	1
CHEMBL1434196	0	1